Judges Scientific (JDG) AI Stock Analysis

• Market Cap: £371.13M
• Dividend Yield: 2.02%
• Average Volume (3M): 19.94K
• Price to Earnings (P/E): 33.7
• Beta (1Y): 0.41
• Revenue Growth: 5.46%
• EPS Growth: -26.44%
• Country: UK
• Employees: 767
• Sector: Technology
• Sector Strength: 88
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 1.39
• Shares Outstanding: 6,651,052
• 10 Day Avg. Volume: 25,550
• 30 Day Avg. Volume: 19,941
• PEG Ratio: 7.16
• Price to Book (P/B): 6.45
• Price to Sales (P/S): 4.20
• P/FCF Ratio: 25.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £7,640.00
• Price Target Upside: 43.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: 5,699.00p ▲(7.12% Upside)

Judges Scientific's strong financial performance is a key strength, supported by robust cash flow and stable balance sheet metrics. However, the technical analysis indicates bearish momentum, and the high P/E ratio suggests the stock may be overvalued. The lack of earnings call data and notable corporate events limits additional insights.

Positive Factors

Cash Generation

Strong cash generation ensures liquidity and operational efficiency, providing the company with the flexibility to invest in growth opportunities and manage debt effectively.

Balance Sheet Health

A stable balance sheet with manageable leverage supports financial resilience, allowing the company to withstand economic fluctuations and invest in strategic initiatives.

Profitability

Consistent profitability indicates efficient operations and a strong market position, enabling sustained investment in innovation and competitive advantage.

Negative Factors

Revenue Challenges

Recent revenue challenges could impact long-term growth if not addressed, potentially limiting the company's ability to expand its market presence and invest in new opportunities.

Earnings Decline

A decline in earnings per share suggests potential operational inefficiencies or market pressures, which could affect investor confidence and future profitability.

Revenue Dip

A decline in revenue may indicate market saturation or increased competition, challenging the company's ability to maintain its growth trajectory and market share.

Judges Scientific Business Overview & Revenue Model

Company Description

Judges Scientific (JDG) is a UK-based group focused on the design, manufacture, and distribution of scientific instruments primarily for the life sciences, healthcare, and industrial sectors. The company operates through various subsidiaries, each specializing in different types of advanced scientific equipment, including analytical and measurement instruments. JDG aims to meet the growing demand for high-quality scientific tools that facilitate research and innovation in various fields.

How the Company Makes Money

Judges Scientific generates revenue through the sale of its scientific instruments and related services. The company has multiple revenue streams, including direct sales of equipment, aftermarket services such as maintenance and calibration, and consumable products that complement its instruments. Significant partnerships with academic institutions, research organizations, and healthcare providers also enhance its market presence and contribute to sales. Additionally, JDG may benefit from government grants and funding for research initiatives in the scientific community, further supporting its earnings.

Judges Scientific Financial Statement Overview

Summary

Judges Scientific exhibits strong financial management across all statements. The income statement reflects steady profitability, with some recent revenue challenges. The balance sheet is stable with manageable leverage, while the cash flow statement highlights excellent cash generation and liquidity. Continued focus on revenue growth and debt management could further enhance financial performance.

Income Statement

The company has shown solid gross profit margins, maintaining stable profitability over the years. The net profit margin is respectable, though there was a slight decline in revenue from 2023 to 2024. The EBIT and EBITDA margins are strong, indicating efficient operations. Overall, the income statement reflects a well-managed financial performance, but the recent revenue dip could be a concern.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio, reflecting a balanced approach to leverage. The equity ratio indicates a solid foundation, though there is room for improvement in reducing liabilities. Return on equity is good, suggesting effective use of shareholder funds. The balance sheet is stable, but managing debt levels could enhance financial health further.

Cash Flow

The company demonstrates strong cash generation capabilities, with a positive operating cash flow to net income ratio. Free cash flow has grown steadily, indicating good financial management. The free cash flow to net income ratio supports a healthy cash conversion cycle, contributing to overall financial stability. The cash flow statement reflects robust liquidity and operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	143.00M	133.60M	136.10M	113.21M	91.29M	79.86M
Gross Profit	23.30M	92.00M	93.60M	21.01M	15.34M	10.02M
EBITDA	31.80M	30.90M	32.20M	29.00M	20.33M	15.17M
Net Income	11.00M	10.40M	9.50M	12.50M	12.68M	8.22M
Balance Sheet
Total Assets	200.30M	205.10M	183.50M	185.79M	88.98M	82.03M
Cash, Cash Equivalents and Short-Term Investments	18.90M	17.90M	13.70M	20.83M	18.41M	15.52M
Total Debt	69.30M	73.60M	65.30M	59.95M	21.32M	26.37M
Total Liabilities	107.60M	117.90M	100.90M	131.33M	45.58M	48.98M
Stockholders Equity	92.50M	86.90M	82.40M	54.24M	42.78M	32.19M
Cash Flow
Free Cash Flow	28.40M	22.10M	20.60M	12.33M	13.44M	10.53M
Operating Cash Flow	32.80M	28.50M	26.50M	20.22M	16.89M	11.79M
Investing Cash Flow	-18.70M	-22.60M	-25.90M	-50.80M	-5.21M	-12.67M
Financing Cash Flow	-300.00K	-1.40M	-7.60M	31.20M	-8.81M	2.34M

Judges Scientific Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5320.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:JDG, the sentiment is Negative. The current price of 5320 is below the 20-day moving average (MA) of 5784.00, below the 50-day MA of 6053.13, and below the 200-day MA of 7006.51, indicating a bearish trend. The MACD of -169.37 indicates Positive momentum. The RSI at 22.76 is Positive, neither overbought nor oversold. The STOCH value of 13.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:JDG.

Judges Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RSW	69 Neutral	£2.53B	30.13	9.15%	2.18%	3.15%	-13.57%
DSCV	68 Neutral	£552.95M	22.56	8.07%	2.18%	-3.23%	58.34%
SXS	63 Neutral	£4.08B	70.23	4.26%	2.06%	0.07%	-78.33%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
JDG	58 Neutral	£371.13M	33.70	12.24%	2.02%	5.46%	-26.44%
GHH	56 Neutral	£155.04M	28.39	4.79%	2.47%	1.74%	359.50%
SOLI	55 Neutral	£82.42M	161.11	0.81%	1.71%	-23.42%	-94.25%

Judges Scientific Corporate Events

Judges Scientific Director Increases Stake in Company

Judges Scientific plc announced that Lushani Kodituwakku, a Non-Executive Director, along with closely associated persons, purchased a total of 1,766 ordinary shares of the company. This transaction increases Kodituwakku’s beneficial holding to 4,237 shares, representing approximately 0.06% of the company’s total issued share capital. This move reflects confidence in the company’s strategic direction and could potentially influence market perception positively.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £6646.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Executives Show Confidence with Share Purchases

Judges Scientific plc announced that several key executives, including the CEO, CFO, COO, Group Business Development Director, and Group Commercial Director, have purchased shares through the company’s Share Incentive Plan. These transactions, conducted on the London Stock Exchange’s AIM Market, reflect a unified confidence in the company’s future prospects and strategic direction, potentially strengthening stakeholder trust and market position.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £6646.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Announces Increase in Share Capital and Voting Rights

Judges Scientific has announced an increase in its total issued share capital to 6,649,452 Ordinary shares as of September 30, 2025. This change affects the total number of voting rights, which shareholders can use to determine their notifiable interest in the company under the Disclosure and Transparency Rules.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £6646.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Reports Robust Interim Results Amidst Challenging Market Conditions

Judges Scientific reported its interim results for the first half of 2025, showing a 15% increase in revenue to £70.2 million and a 17% rise in adjusted pre-tax profit to £12.6 million, despite a challenging trading environment. The company faced difficulties due to reduced US federal government research funding and trading challenges in certain businesses, but saw strong performance from Geotek and a recovery in China/Hong Kong. The interim dividend was increased by 10%, and the company remains focused on addressing trading challenges and supporting organic growth, while maintaining a solid order book and financial strength.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £6202.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Executives Participate in Share Incentive Plan

Judges Scientific plc announced the purchase of ordinary shares by the Trustees of the Share Incentive Plan, involving key executives including the CEO, CFO, COO, Group Business Development Director, and Group Commercial Director. The transactions, conducted on the London Stock Exchange’s AIM Market, reflect the company’s commitment to aligning management interests with shareholder value, potentially strengthening stakeholder confidence in the company’s strategic direction.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £6202.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific to Host Investor Presentation Webinar

Judges Scientific PLC announced an upcoming investor presentation webinar scheduled for 18 September 2025, covering the first half of the year. The presentation, led by key executives, will provide insights into the company’s performance and strategic direction, with opportunities for shareholders to engage through questions. This initiative reflects Judges Scientific’s commitment to transparency and stakeholder engagement, potentially enhancing investor confidence and reinforcing its market position.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £6202.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.